Clinical Trials Directory

Trials / Completed

CompletedNCT05353634

Metagenomic Sequencing in Clinical Infectious Diseases

Research on the Diagnostic Application of Metagenomic Sequencing in Clinical Infectious Diseases

Status
Completed
Phase
Study type
Observational
Enrollment
2,022,097 (actual)
Sponsor
Liaocheng People's Hospital · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Progress in the diagnosis of infectious pathogens depends on the development of effective methods and the discovery of suitable biomarkers. There are several kinds of methods that have been used in diagnosis of various pathogens, such as microscopic examination, culture, serologic diagnosis or molecular approaches, etc. However, these methods have similar limitations, that is, the single detection of reagents. More importantly, physicians seldom consider infections with rare pathogens. Recently developed metagenomic next-generation sequencing (mNGS) has the capability to overcome limitations of traditional diagnostic tests. This new technology could identify all pathogens directly from sample with a single run in a hypothesis-free and culture-independent manner. Studies have shown that mNGS is more sensitive than traditional culture method in clinical conditions such as blood stream, respiratory and general infections. More importantly, due to unbiased sampling, mNGS is theoretically able to identify not only known but also unexpected pathogens or even discovery novel organisms. It should be noted that mNGS also has some limitations such as human genome contamination and possibly environmental microbial contamination. The vast majority of reads in mNGS are derived from human host. This would impede the overall analytical sensitivity of mNGS for pathogen detection. Host depletion methods or targeted sequencing may help to partially mitigate this disadvantage. As mNGS could not, by itself, define whether the detected microbe is the causative pathogen or environmental microorganism, a multidisciplinary discussion by clinicians, microbiologists as well as the lab technicians is required to interpret the result.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTEffects of mNGS on infected patientsThe impact of mNGS on infected patients, including diagnostic value, drug selection, treatment prognosis, economic burden, etc.

Timeline

Start date
2020-06-10
Primary completion
2021-10-16
Completion
2022-04-20
First posted
2022-04-29
Last updated
2022-04-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05353634. Inclusion in this directory is not an endorsement.